Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) has reported positive results from its ongoing IGNITE DMD Phase I/II clinical trial of SGT-001, aimed at treating Duchenne muscular dystrophy. Data presented at the Child Neurology Society 50th Annual Meeting indicated improvements in pulmonary function in patients receiving SGT-001 compared to untreated controls. Specifically, patients showcased significant percentage increases in peak expiratory flow and forced expiratory volume one year post-administration. These findings suggest the potential clinical benefit of SGT-001 in enhancing patient outcomes.

Solid Biosciences (Nasdaq: SLDB) reports positive findings from the ongoing IGNITE DMD Phase I/II trial of SGT-001, a gene therapy for Duchenne muscular dystrophy. The data, presented at the World Muscle Society 2021 Virtual Congress, shows sustained functional benefits and patient-reported outcomes 1.5 years post-treatment. Key metrics include a mean decrease of 1.7 points in North Star Ambulatory Assessment (NSAA) compared to a projected decline of 4.5 points, and a 15.3-meter increase in the 6-Minute Walk Test (6MWT). No new safety concerns were reported over 3.5 years.

Solid Biosciences Inc. (Nasdaq: SLDB) announced the upcoming presentation of long-term data from patients 4-6 in the IGNITE DMD Phase I/II clinical trial of SGT-001 for Duchenne muscular dystrophy. The data will be presented by Dr. Vamshi Rao at the World Muscle Society 2021 Virtual Congress on September 23, 2021. SGT-001 aims to address the genetic cause of Duchenne by delivering a synthetic dystrophin gene via an adeno-associated viral vector. The therapy has received multiple designations from regulatory authorities, reflecting its potential in treating Duchenne.

Solid Biosciences (Nasdaq: SLDB) announces participation of Dr. Joel Schneider and Dr. Carl Morris at the SVB Leerink CybeRx Series and Chardan's 5th Annual Genetic Medicines Conference. The fireside chat from the Chardan conference will be available via live webcast on October 5, 2021, at 2:30 p.m. ET on the company's investor relations website. Solid Biosciences is committed to developing transformative therapies for Duchenne muscular dystrophy and is advancing its lead gene therapy candidate, SGT-001.

Solid Biosciences (Nasdaq: SLDB) will showcase its advanced AAV gene therapy manufacturing capabilities at the 11th Annual World Orphan Drug Congress USA 2021 on August 27 at 11:15 AM ET. Chief Operating Officer Joel Schneider, PhD, will discuss the scalable approach to producing AAV gene therapies targeting Duchenne muscular dystrophy (Duchenne). Following his talk, he will join a panel discussion on manufacturing strategies at 11:55 AM ET. Solid’s gene therapy candidate, SGT-001, aims to address the genetic cause of Duchenne and has received several designations to expedite development.

Solid Biosciences Inc. (Nasdaq: SLDB) has announced the grant of inducement awards to its new Senior Vice President of Finance, Michael Inbar. This decision was approved by independent directors on July 27, 2021. The inducement grant includes options to purchase 118,000 shares of common stock and restricted stock units for 59,000 shares, both vesting over four years. The options have a ten-year term with an exercise price set at $2.51 per share, reflecting the closing price on August 16, 2021.

Solid Biosciences Inc. (Nasdaq: SLDB) announced that Michael Inbar, CPA, MBA, has joined as Senior Vice President, Finance, effective August 16, 2021. Inbar brings extensive expertise in public accounting and finance team management from his previous roles at Syros Pharmaceuticals and Acronis. CEO Ilan Ganot emphasized the importance of Inbar's experience for the company's growth and commitment to improving patients' lives through transformative therapies for Duchenne muscular dystrophy. Inbar expressed excitement about being part of a team focused on significant patient outcomes.

Solid Biosciences (Nasdaq: SLDB) reported progress in its clinical trials and R&D pipeline during Q2 2021. Key highlights include advancing patient dosing in the IGNITE DMD trial, with the next dosing expected in Q4 2021. The company holds approximately $249 million in cash, enabling operations into Q4 2022. Collaboration revenue for the quarter reached $3.6 million, a notable increase from the previous year. However, R&D expenses rose to $15.5 million, reflecting increased costs related to SGT-001.

Solid Biosciences Inc. (Nasdaq: SLDB) has granted an inducement award to Dr. Roxana Dreghici, the newly appointed Senior Vice President of Clinical Development. This grant, approved by independent directors on June 16, 2021, includes an option to purchase 230,000 shares of common stock at an exercise price of $3.77 per share, reflecting the closing price on July 1, 2021. The option vests over four years, contingent on Dr. Dreghici's continued employment. Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, particularly through its lead gene therapy candidate, SGT-001.